Market Place
Sourcing Support
Perrigo Reports Q3 Financial Results from Continuing Operations
06 Nov 2024 //
PR NEWSWIRE
Perrigo Announces Quarterly Dividend
01 Nov 2024 //
PR NEWSWIRE
Perrigo Launches Infant Formula With Dr. Browns
26 Sep 2024 //
PR NEWSWIRE
Perrigo Announces Closing Of Senior Notes Offering By Finance Subsidiary
17 Sep 2024 //
PR NEWSWIRE
Perrigo Prices Senior Notes Offering By Finance Subsidiary
12 Sep 2024 //
PR NEWSWIRE
Perrigo Appoints Charles as Executive VP, General Counsel, and Secretary
04 Sep 2024 //
PR NEWSWIRE
Perrigo to Attend the Piper Sandler Growth Frontiers Conference
27 Aug 2024 //
PR NEWSWIRE
Perrigo Appoints David Ball As EVP And Chief Brand And Digital Officer
19 Aug 2024 //
PR NEWSWIRE
Perrigo picks Bayer alum as inaugural brand and digital chief
19 Aug 2024 //
FIERCE PHARMA
Perrigo recalls 16,500 cans of its infant formula
08 Aug 2024 //
REUTERS
Perrigo Reports Second Quarter 2024 Financial Results From Continuing Operations
02 Aug 2024 //
PR NEWSWIRE
Perrigo Announces Quarterly Dividend
01 Aug 2024 //
PR NEWSWIRE
Perrigo to Attend the Canaccord Genuity 44th Annual Growth Conference
31 Jul 2024 //
PR NEWSWIRE
Perrigo to Release Second Quarter 2024 Financial Results on August 2, 2024
19 Jul 2024 //
PR NEWSWIRE
Perrigo to Attend Oppenheimer 24th Annual Consumer Growth & E-Commerce Conf
28 May 2024 //
PR NEWSWIRE
Perrigo Announces Quarterly Dividend
01 May 2024 //
PR NEWSWIRE
Perrigo agrees to sell rare disease unit to Esteve for €275 million
26 Apr 2024 //
PRESS RELEASE
Perrigo to Divest HRA Pharma Rare Diseases for Up to €275M
25 Apr 2024 //
PR NEWSWIRE
Perrigo to Release First Quarter 2024 Financial Results on May 7, 2024
23 Apr 2024 //
PR NEWSWIRE
Perrigo`s Opill OTC birth control med teams up with WNBA
10 Apr 2024 //
FIERCE PHARMA
Opill and WNBA Team Up for Groundbreaking Partnership
09 Apr 2024 //
PR NEWSWIRE
Perrigo Commences Shipments of Opill® to Retailers Nationwide
04 Mar 2024 //
PR NEWSWIRE
Perrigo to Attend UBS Global Consumer and Retail Conference
29 Feb 2024 //
PR NEWSWIRE
Perrigo Reports Fourth Quarter & Fiscal Year 2023 Financial Results
27 Feb 2024 //
PR NEWSWIRE
Perrigo plots hundreds of job cuts amid restructuring plan
27 Feb 2024 //
FIERCE PHARMA
Perrigo Increases its Quarterly Dividend
26 Feb 2024 //
PR NEWSWIRE
Perrigo to Release Fourth Quarter and Fiscal Year 2023 Financial Results
13 Feb 2024 //
PR NEWSWIRE
Perrigo Announces Early Results of Cash Tender Offer for Notes
29 Nov 2023 //
PRESS RELEASE
Perrigo Announces Cash Tender Offer for Notes
10 Nov 2023 //
PR NEWSWIRE
Perrigo Reports Third Quarter Fiscal Year 2023 Financial Results
07 Nov 2023 //
PR NEWSWIRE
Perrigo Announces Quarterly Dividend
02 Nov 2023 //
PR NEWSWIRE
Perrigo to Attend Upcoming Consumer Investor Conferences
31 Oct 2023 //
PR NEWSWIRE
Perrigo Company plc Shares Approach 52-Week Low - Market Mover
29 Oct 2023 //
NASDAQ
Perrigo to Release Third Quarter 2023 Financial Results on November 7, 2023
24 Oct 2023 //
PR NEWSWIRE
Perrigo Announces Leadership Update
11 Sep 2023 //
PR NEWSWIRE
Perrigo to Attend Upcoming Consumer Investor Conferences
24 Aug 2023 //
PR NEWSWIRE
Perrigo Reports Second Quarter Fiscal Year 2023 Financial Results
08 Aug 2023 //
PR NEWSWIRE
Perrigo Announces Quarterly Dividend
02 Aug 2023 //
PR NEWSWIRE
Perrigo to Release Second Quarter 2023 Financial Results
25 Jul 2023 //
PR NEWSWIRE
FDA Approves First Nonprescription Daily Oral Contraceptive
14 Jul 2023 //
FDA
Perrigo Appoints Patrick Lockwood-Taylor as President and CEO
08 Jun 2023 //
PR NEWSWIRE
Perrigo to Host 1x1 Investor Meetings at the 23rd Annual Oppenheimer
24 May 2023 //
PR NEWSWIRE
Perrigo Announces U.S. FDA Approval For Nicotine Coated Mint Lozenge
17 May 2023 //
PR NEWSWIRE
Perrigo Announces U.S. FDA Approval For Nicotine Coated Mint Lozenge
16 May 2023 //
PR NEWSWIRE
U.S. FDA advisers back Perrigo birth control pill for over-the-counter use
12 May 2023 //
REUTERS
Perrigo`s OTC birth control pill aces FDA expert meeting
10 May 2023 //
FIERCE PHARMA
Perrigo Announces Chief Executive Officer Retirement and Succession Plan
09 May 2023 //
PRESS RELEASE
Perrigo Reports 1Q Fiscal Year 2023 Financial Results From Continuing Operations
09 May 2023 //
PR NEWSWIRE
FDA raises questions about real-world use of OTC birth control
09 May 2023 //
FIERCE PHARMA
Perrigo Pays For Growth Drivers In Q1 Results
08 May 2023 //
PRESS RELEASE
FDA staff raises concerns over OTC use of Perrigo`s birth control pill
06 May 2023 //
REUTERS
Perrigo Announce Quarterly Dividend
04 May 2023 //
PR NEWSWIRE
Perrigo to Release First Quarter 2023 Financial Results on May 9, 2023
25 Apr 2023 //
PR NEWSWIRE
Perrigo Announces Date for Joint FDA Advisory Committee Meeting to Review Opill
28 Mar 2023 //
PR NEWSWIRE
Perrigo`s OTC bid for contraceptive Opill secures May FDA adcomm
28 Mar 2023 //
FIERCE PHARMA
Perrigo Announces Voluntary Recall of Limited Quantity of Powdered Formula
17 Mar 2023 //
PRESS RELEASE
Perrigo to Present at 12th Annual UBS Global Consumer and Retail Conference
02 Mar 2023 //
PRESS RELEASE
Perrigo Announces FDA Approval of the Store Brand OTC Equivalent of Advil
01 Mar 2023 //
PR NEWSWIRE
Perrigo Launches its 3-Year Optimize and Accelerate Strategic Plan
28 Feb 2023 //
PRESS RELEASE
Perrigo Reports Fourth Quarter & Fiscal Year 2022 Financial Results
27 Feb 2023 //
PR NEWSWIRE
